3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate inhibits cancer cell invasion in vitro and tumour growth in vivo

British Journal of Cancer

Volumn 88, Issue 7, 2003, Pages 1111-1118

  Kempen, I ^a   Papapostolou, D ^b   Thierry, N ^b   Pochet, L ^c   Counerotte, S ^a   Masereel, B ^c   Foidart, J M ^a   Reboud Ravaux, M ^b   Noel A ^a   Pirotte, B ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b INSTITUT JACQUES MONOD   (France)

^c UNIVERSITY OF NAMUR   (Belgium)

Author keywords

Cell invasion; Coumarin derivatives; Tumour growth

Indexed keywords

3 BROMOPHENYL 6 ACETOXYMETHYL 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 CHLOROPHENYL 6 ACETOXYMETHYL 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; COUMARIN DERIVATIVE; GELATINASE INHIBITOR; GI 129471; METALLOPROTEINASE INHIBITOR; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER GRAFT; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; CARBOXYLIC ACIDS; COUMARINS; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037692876     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600856     Document Type: Article

References (30)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
2. Attia MA, Weiss DW (1966) Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26(8): 1787-1800
3. Bender ML, Begue-Canton ML, Blakeley RL, Brubacher LJ, Feder J, Gunter CR, Kezdy FJ, Killheffer JVJ, Marshall TH, Miller CG, Roeske RW, Stoops JK (1966) The determination of the concentration of hydrolytic enzyme solutions: alpha-chymotrypsin, trypsin, papain, elastase, subtilisin and acetylcholinesterase. J Am Chem Soc 88: 5890-8913
4. Blacher S, Devy L, Burbridge M-F, Roland G, Tucker G, Noël A, Foidart JM (2001) Improved quantification of angiogenesis in the rat aortic ring assay. Angiogenesis 4(2): 133-142
5. Chase TJ, Shaw E (1970) Titration of trypsin, plasmin, and thrombin with p-nitrophenyl p′-guanidinobenzoate HCl. Methods Enzymol 19: 20-27
6. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564): 2387-2392
7. Crescimano C, Foidart JM, Noël A, Polette M, Maquoi E, Birembaut Ph, Baramoua E, Kaufmann P, Castelluci M (1996) Cloning of choriocarcinoma cells shows that invasion correlates with the expression and activation of gelatinase A. Exp Cell Res 227: 240-251
8. Doucet C, Pochet L, Thierry N, Pirotte B, Delarge J, Reboud-Ravaux M (1999) 6-Substitued-2-oxo-2H-1-benzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase. J Med Chem 42: 4161-4171
9. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3): 161-174
10. Frankenne F, Noël A, Bajou K, Sounni NE, Goffin F, Masson V, Munaut C, Remacle A, Foidart JM (1999) Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy. Emerging Ther Targets 3(3): 1-13
11. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1): 57-70
12. Hooper JD, Clements JA, Quigley JP, Antalis TM (2001) Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 276: 857-860
13. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(259): 680-685
14. Liotta LA (1986) Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 46(1): 1-7
15. Maquoi E, Munaut C, Colige A, Lambert C, Frankenne F, Noël A, Grams F, Krell HW, Foidart JM (1999) Paradoxical stimulation of matrix metalloproteinase-9 expression in HT1080 cells by a broad-spectrum hydroxamate-based matrix metalloproteinase inhibitor. Ann NY Acad Sci 30(878): 744-764
16. Masson V, Devy L, Grignet-Debrus C, Berndt S, Bajou K, Blacher S, Roland G, Chang Y, Fong F, Carmeliet P, Foidart JM, Noël A (2002) Mouse aortic ring assay: a new approach of the molecular genetics of angiogenesis. Biol Proced Online 4(1): 24-31
17. Noël A, Bajou K, Masson V, Frankenne F, Rakic JM, Lambert V, Carmeliet P, Foidart JM (1999) Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis Proteolysis 13(6): 220-225
18. Noël A, Callé A, Emonard P, Nusgens BV, Simar L, Foidart J, Lapière C, Foidart JM (1991) Invasion of reconstituted basement membrane matrix is not correlated to the malignant metastatic cell phenotype. Cancer Res 51: 405-414
19. Noël A, Simon N, kleinman HK, Raus J, Foidart JM (1992) Basement membrane components (matrigel) promote human breast adenocarcinoma MCF7 cells tumorigenicity and provide an in vivo model to assess cell responsiveness to estrogen. Biochem Pharmacol 43: 1263-1267
20. Pochet L, Doucet C, Dive G, Wouters J, Masereel B, Reboud-Ravaux M, Pirotte B (2000) Coumarinic derivatives as mechanism-based inhibitors of α-chymotrypsin and human leukocyte elastase. Bioorg Med Chem 8: 1489-1501
21. Pochet L, Doucet C, Schynts M, Thierry N, Boggetto N, Pirotte B, Jiang KY, Masereel B, de Tullio P, Delarge J, Reboud-Ravaux M (1996) Esters and amides of 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-carboxylic acid as inhibitors of α-chymotrypsin: significance of the 'aromatic' nature of the novel ester-type coumarin for strong inhibitory activity. J Med Chem 39(13): 2579-2585
22. Powers JC, Gupton BF (1977) Reaction of serine proteases with aza-amino acid and aza-peptide derivatives. Methods Enzymol 46: 208-216
23. Reboud-Ravaux M, Desvages G (1984) Inactivation of human high- and low-molecular-weight urokinases. Analysis of their active site. Biochim Biophys Acta 791(3): 333-341
24. Reboud-Ravaux M, Desvages G, Chapeville F (1982) Irreversible inhibition and peptide mapping of urinary plasminogen activator urokinase. FEBS Lett 140(1): 58-62
25. Schmitt M, Wilhelm O, Reuning U, Krüger A, Harbeck N, Lengyel E, Graeff H, Gänsbacher B, Kessler H, Bürgle M, Stürzebecher J, Sperl S, Magdolen V (2000) The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis 14(2/3): 114-132
26. Stetler-Stevenson WG, Liotta LA, Kleiner Jr DE (1993) Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7(15): 1434-1441
27. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS (2000) Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275(34): 26333-26342
28. Wheeler DJ, Parveen S, Pollock K, Williams RJ (1998) Inhibition of sCD23 and immunoglobulin E release from human B cells by a metalloproteinase inhibitor, GI 129471. Immunology 95(1): 105-110
29. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (2 edn). Br J Cancer 77(1): 1-10
30. Zetter BR (1998) Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424